CN105658240A - 用于缀合可活化抗体的组合物和方法 - Google Patents

用于缀合可活化抗体的组合物和方法 Download PDF

Info

Publication number
CN105658240A
CN105658240A CN201480043966.1A CN201480043966A CN105658240A CN 105658240 A CN105658240 A CN 105658240A CN 201480043966 A CN201480043966 A CN 201480043966A CN 105658240 A CN105658240 A CN 105658240A
Authority
CN
China
Prior art keywords
antibody
activatable antibody
target
seq
activatable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480043966.1A
Other languages
English (en)
Chinese (zh)
Inventor
A.W.康拉迪
S.辛格
H.B.洛曼
L.R.德斯诺耶斯
T.W.梁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Priority to CN202210873109.0A priority Critical patent/CN116063479A/zh
Publication of CN105658240A publication Critical patent/CN105658240A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480043966.1A 2013-06-04 2014-06-04 用于缀合可活化抗体的组合物和方法 Pending CN105658240A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210873109.0A CN116063479A (zh) 2013-06-04 2014-06-04 用于缀合可活化抗体的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361830913P 2013-06-04 2013-06-04
US61/830913 2013-06-04
US201361919935P 2013-12-23 2013-12-23
US61/919935 2013-12-23
PCT/US2014/040931 WO2014197612A1 (en) 2013-06-04 2014-06-04 Compositions and methods for conjugating activatable antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210873109.0A Division CN116063479A (zh) 2013-06-04 2014-06-04 用于缀合可活化抗体的组合物和方法

Publications (1)

Publication Number Publication Date
CN105658240A true CN105658240A (zh) 2016-06-08

Family

ID=51023194

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480043966.1A Pending CN105658240A (zh) 2013-06-04 2014-06-04 用于缀合可活化抗体的组合物和方法
CN202210873109.0A Pending CN116063479A (zh) 2013-06-04 2014-06-04 用于缀合可活化抗体的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210873109.0A Pending CN116063479A (zh) 2013-06-04 2014-06-04 用于缀合可活化抗体的组合物和方法

Country Status (10)

Country Link
US (4) US9517276B2 (enExample)
EP (1) EP3003387A1 (enExample)
JP (2) JP6660294B2 (enExample)
KR (1) KR20160018579A (enExample)
CN (2) CN105658240A (enExample)
AU (2) AU2014274982B2 (enExample)
BR (1) BR112015030514A2 (enExample)
CA (1) CA2913732A1 (enExample)
RU (1) RU2015156888A (enExample)
WO (1) WO2014197612A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484781A (zh) * 2018-04-23 2018-09-04 深圳市国创纳米抗体技术有限公司 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用
CN112285361A (zh) * 2020-09-27 2021-01-29 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114981287A (zh) * 2020-01-06 2022-08-30 西托姆克斯治疗公司 阿里他汀相关化合物、经缀合阿里他汀化合物及其使用方法
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CA2871458C (en) 2012-04-27 2020-06-23 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9517276B2 (en) * 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
HRP20220553T1 (hr) * 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
WO2015089449A2 (en) 2013-12-12 2015-06-18 Stem Centrx, Inc. Novel anti-dpep3 antibodies and methods of use
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3244907B1 (en) * 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
JP6879932B2 (ja) * 2015-04-06 2021-06-02 サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
WO2016210447A1 (en) * 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
CN106519037B (zh) * 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
ES2873846T5 (en) 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN105267982A (zh) * 2015-11-20 2016-01-27 暨南大学 一种rhHER2抗体与MMAE偶联物及其制备方法与应用
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
AR112048A1 (es) * 2016-05-09 2019-09-18 Celgene Corp Anticuerpos cd47 y métodos de uso de los mismos
EA201991353A1 (ru) 2016-12-09 2019-11-29 Двухвалентные антитела, маскированные спирализованными спиралями
JP2020531045A (ja) 2017-07-14 2020-11-05 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ１６６抗体およびその使用
KR20240170847A (ko) 2017-09-08 2024-12-04 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
IL321773A (en) 2017-10-14 2025-08-01 Cytomx Therapeutics Inc Activatable antibodies and methods for preparing them
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
EP3794022A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019241430A2 (en) * 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
MX2021001085A (es) 2018-07-31 2021-03-31 Amgen Inc Formulaciones y composiciones farmaceuticas que comprenden una proteina de union a antigeno enmascarada.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120248140A (zh) 2018-12-06 2025-07-04 西托姆克斯治疗公司 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
US20220233705A1 (en) * 2019-02-26 2022-07-28 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
CN120484127A (zh) 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
JP7754723B2 (ja) 2019-05-14 2025-10-15 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
WO2022081541A1 (en) * 2020-10-13 2022-04-21 Chan Zuckerberg Biohub, Inc. Compositions and methods involving antibody constructs
WO2023070353A1 (en) * 2021-10-27 2023-05-04 Adagene Pte. Ltd. Anti-cd47 antibodies and methods of use thereof
IL318313A (en) 2022-07-12 2025-03-01 Cytomx Therapeutics Inc EPCAM antibody conjugates and their uses
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010945A1 (en) * 2004-03-02 2009-01-08 Seattle Genetics, Inc. Partially Loaded Antibodies And Methods Of Their Conjugation
WO2009025846A2 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2012059882A2 (en) * 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102482347A (zh) * 2009-01-12 2012-05-30 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2006071441A2 (en) * 2004-11-30 2006-07-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
KR20150126978A (ko) 2005-06-20 2015-11-13 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
US7666817B2 (en) 2005-08-31 2010-02-23 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
WO2007105027A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
PL2694111T3 (pl) 2011-04-01 2017-01-31 Wyeth Llc Koniugaty przeciwciało-lek
CA2833477A1 (en) * 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
US8871908B2 (en) * 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
CN104220458B (zh) * 2012-02-24 2018-08-14 阿特根公司 结合有含半胱氨酸残基的基序的修饰抗体，含该修饰抗体的修饰抗体-药物缀合物以及其制造方法
EP2863948B1 (en) * 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9856314B2 (en) * 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
WO2014004694A1 (en) 2012-06-26 2014-01-03 Massachusetts Institute Of Technology Reversible masking of pore-forming proteins for macromolecular delivery
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
JP6328648B2 (ja) * 2012-10-24 2018-05-23 ポリセリックス・リミテッド 新規薬物−タンパク質コンジュゲート
AU2014204015A1 (en) * 2013-01-04 2015-07-09 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
US9517276B2 (en) * 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010945A1 (en) * 2004-03-02 2009-01-08 Seattle Genetics, Inc. Partially Loaded Antibodies And Methods Of Their Conjugation
WO2009025846A2 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
CN102482347A (zh) * 2009-01-12 2012-05-30 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
WO2012059882A2 (en) * 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALAIN BECK等: "Fourth World Antibody-Durg Conjugate Summit", 《MABS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484781A (zh) * 2018-04-23 2018-09-04 深圳市国创纳米抗体技术有限公司 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用
CN108484781B (zh) * 2018-04-23 2021-05-04 深圳市国创纳米抗体技术有限公司 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用
CN114981287A (zh) * 2020-01-06 2022-08-30 西托姆克斯治疗公司 阿里他汀相关化合物、经缀合阿里他汀化合物及其使用方法
CN112285361A (zh) * 2020-09-27 2021-01-29 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途

Also Published As

Publication number Publication date
RU2015156888A (ru) 2017-07-14
KR20160018579A (ko) 2016-02-17
JP2020079292A (ja) 2020-05-28
JP2016521707A (ja) 2016-07-25
RU2015156888A3 (enExample) 2018-05-30
AU2014274982A1 (en) 2015-12-10
CA2913732A1 (en) 2014-12-11
AU2014274982B2 (en) 2019-12-05
US20250099606A1 (en) 2025-03-27
WO2014197612A9 (en) 2015-03-19
WO2014197612A1 (en) 2014-12-11
BR112015030514A2 (pt) 2017-08-29
JP6660294B2 (ja) 2020-03-11
US20170072067A1 (en) 2017-03-16
US9517276B2 (en) 2016-12-13
US11992528B2 (en) 2024-05-28
US20150005477A1 (en) 2015-01-01
AU2020201405A1 (en) 2020-03-12
US20220088192A1 (en) 2022-03-24
CN116063479A (zh) 2023-05-05
EP3003387A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
US20250099606A1 (en) Compositions and methods for conjugating activatable antibodies
CN113271956B (zh) 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
CN114685611B (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN106163556B (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
JP2023159314A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
AU2016258988A1 (en) Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
BR122022003994B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo os mesmos, uso terapêutico dos mesmos, molécula de ácido nucleico isolada, vetor, bem como métodos de produzir um polipeptídeo isolado e de fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo
BR112017015468B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo-os, uso terapêutico destes, molécula de ácido nucleico isolada, vetor, método para produzir um polipeptídeo isolado e método para fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160608